UNSPSC 51113600: Alkylating agent cytokines

This classification denotes immuno-proteins that affect cell signaling, and include proteins such as chemokines, interferons, interleukins, and lymphokines, and that constitute reactive chemicals that introduce into biologically active molecules alkyl radicals and thereby disrupt functioning of the same, substances called alkyl-ating agents, thus the term ALKYLATING AGENT CYTOKINES.

UNSPSC 51113600 Alkylating agent cytokines is a Class code that in recent state and local procurement activity encompasses pharmaceutical supply arrangements for specialty medications, particularly within state health benefit and pharmacy programs. The Texas Health and Human Services Commission's April 2026 Request for Information on direct-to-manufacturer prescription fulfillment signals that states are exploring alternative distribution models for pharmaceutical products beyond traditional pharmacy benefit managers and group purchasing organizations. The work solicited under this code involves vendor capability assessment for direct contracting relationships, negotiated net pricing strategies, and outcomes-based or value-based pharmaceutical agreements designed to optimize cost management and prescription fulfillment efficiency within state employee health plans and Medicaid programs.

State health and human services agencies appear to be the primary issuing bodies under this code, with the Texas HHS Commission conducting preliminary market research on direct pharmaceutical distribution arrangements. The recent activity concentrates in Texas as of mid-2026, with no additional state or local opportunities identified in the source. The Texas HHS Commission RFI (HHS0017013, posted April 3, 2026, with response deadline April 3, 2026) sought vendor experience in direct contracting with self-insured employers and government health plans, flexibility in negotiated net pricing without rebates, and implementation capacity for value-based agreements; this RFI functions as an exploratory procurement mechanism to inform future formal RFP development rather than a binding competitive solicitation with established award values or timelines.